Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AIO-Studien-gGmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 2007-01-01

Employees: 11

Market Cap: -

Website: http://www.aio-studien-ggmbh.de

Clinical Trials

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Phase 2

Completed

Conditions: Her2-negative Metastatic Breast Cancer
Her2-negative Locally Advanced Breast Cancer

Interventions: Drug: Vinorebine, Everolimus
Drug: Vinorelbine

First Posted Date: 2012-01-27

Last Posted Date: 2017-08-09

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 139

Registration Number: NCT01520103

Locations: 🇩🇪
Hämatologisch-onkologische Gemeinschaftspraxis, Münster, Münster, Germany

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Phase 2

Completed

Conditions: Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Interventions: Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel

First Posted Date: 2012-01-05

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 42

Registration Number: NCT01504256

Locations: 🇩🇪
Prof. Dr. F. Lordick, Leipzig, Germany

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Adenocarcinoma of the Stomach

Interventions: Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab
Drug: Post-operative treatment trastuzumab mono therapy

First Posted Date: 2011-11-16

Last Posted Date: 2017-06-19

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 53

Registration Number: NCT01472029

Locations: 🇩🇪
Tagestherapiezentrum am ITM & III. Medizinische Klinik Universitätsmedizin Mannheim, Mannheim, Germany

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: FOLFOXIRI + Panitumumab
Drug: FOLFOXIRI

First Posted Date: 2011-04-04

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 93

Registration Number: NCT01328171

Locations: 🇩🇪
Klinikum Esslingen, Esslingen, Baden-Württemberg, Germany
🇩🇪
SLK-Kliniken Heilbronn GmbH, Heilbronn, Baden-Württemberg, Germany
🇩🇪
Ortenau Klinikum, Lahr, Baden-Württemberg, Germany

and more 16 locations

ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction

Phase 2

Completed

Conditions: Stomach Neoplasms
Gastroesophageal Junction Neoplasms

Interventions: Drug: Epirubicin, Cisplatin, Capecitabine, Panitumumab
Drug: Epirubicin, Cisplatin, Capecitabine

First Posted Date: 2010-11-04

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 171

Registration Number: NCT01234324

Locations: 🇩🇪
AIO-Studien gGmbH, Berlin, Germany

Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers

Phase 2

Completed

Conditions: Gastrointestinal Cancers
Malignant Ascites

Interventions: Other: Placebo
Drug: Bevacizumab

First Posted Date: 2010-09-13

Last Posted Date: 2015-04-13

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 53

Registration Number: NCT01200121

Locations: 🇩🇪
Klinikum Ludwigsburg, Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Diabetologie, Ludwigsburg, Baden-Württemberg, Germany
🇩🇪
Onkologische Schwerpunktpraxis, Wendlingen, Baden-Württemberg, Germany
🇩🇪
Klinikum Deggendorf, Medizinische Klinik II, Deggendorf, Bayern, Germany

and more 23 locations

Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

First Posted Date: 2009-09-09

Last Posted Date: 2015-09-01

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 853

Registration Number: NCT00973609

Locations: 🇩🇪
AIO-Studien gGmbH, Berlin, Germany

Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Oxaliplatin, Capecitabine
Drug: Oxaliplatin, Capecitabine, Panitumumab

First Posted Date: 2009-08-03

Last Posted Date: 2013-03-04

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 9

Registration Number: NCT00950820

Locations: 🇩🇪
AIO-Studien-gGmbH, Berlin, Germany

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Placebo
Drug: Sorafenib
Drug: Oxaliplatin or Irinotecan
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2009-04-28

Last Posted Date: 2013-03-04

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 101

Registration Number: NCT00889343

Locations: 🇩🇪
Medizinisches Versorgungszentrum am Siloah St. Trudpert Klinikum, Pforzheim, Baden-Würtemberg, Germany
🇩🇪
Ostalb-Klinikum Aalen, Medizinische Klinik 1, Aalen, Baden-Württemberg, Germany
🇩🇪
Kreiskliniken Esslingen gGmbH, Klinik Nürtingen, Medizinische Klinik I, Nürtingen, Baden-Württemberg, Germany

and more 53 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy